Genovate Biotechnology Co (ROCO:4130) PE Ratio: 263.24 (As of Jul. 14, 2026) — 172% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4130 Genovate Biotechnology Co Ltd ROCO:4130
72 GF Score
Price NT$26.85
GF Value NT$22.20
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Genovate Biotechnology Co PE Ratio?

Genovate Biotechnology Co ROCO:4130 -4.62% 72 PE Ratio is 263.24 as of Jul. 14, 2026, which is 172% above its 10-year median of 96.86. GuruFocus rates ROCO:4130 with a GF Score™ of 72/100 and a GF Value™ of NT$22.20 (Modestly Overvalued). The stock has 3 warning signs investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-07-14), Genovate Biotechnology Co's share price is NT$26.85. Genovate Biotechnology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.10. Therefore, Genovate Biotechnology Co's PE Ratio for today is 263.24.

During the past 13 years, Genovate Biotechnology Co's highest PE Ratio was 7789.76. The lowest was 20.74. And the median was 96.86.

Genovate Biotechnology Co's EPS (Diluted) for the three months ended in Dec. 2025 was NT$-0.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.10.

As of today (2026-07-14), Genovate Biotechnology Co's share price is NT$26.85. Genovate Biotechnology Co's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.10. Therefore, Genovate Biotechnology Co's PE Ratio without NRI ratio for today is 263.24.

During the past 13 years, Genovate Biotechnology Co's highest PE Ratio without NRI was 7789.76. The lowest was 20.74. And the median was 97.10.

Genovate Biotechnology Co's EPS without NRI for the three months ended in Dec. 2025 was NT$-0.04. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.10.

During the past 12 months, Genovate Biotechnology Co's average EPS without NRI Growth Rate was -54.50% per year.

During the past 13 years, Genovate Biotechnology Co's highest 3-Year average EPS without NRI Growth Rate was 314.10% per year. The lowest was -81.70% per year. And the median was 1.85% per year.

Genovate Biotechnology Co's EPS (Basic) for the three months ended in Dec. 2025 was NT$-0.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.10.

Back to Basics: PE Ratio


Genovate Biotechnology Co  (ROCO:4130) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Genovate Biotechnology Co PE Ratio Related Terms


Genovate Biotechnology Co PE Ratio Historical Data

* Premium members only.

The historical data trend for Genovate Biotechnology Co's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genovate Biotechnology Co PE Ratio Chart

Genovate Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7,620.75 At Loss 99.28 92.72 276.57

Genovate Biotechnology Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 92.72 125.81 119.28 218.86 276.57

ROCO:4130 vs VRTX, REGN, ALNY: PE Ratio Comparison

For the Biotechnology subindustry, Genovate Biotechnology Co's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genovate Biotechnology Co PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genovate Biotechnology Co's PE Ratio distribution charts can be found below:

* The bar in red indicates where Genovate Biotechnology Co's PE Ratio falls into.


ROCO:4130
72GF Score
Genovate Biotechnology Co Ltd ROCO:4130
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genovate Biotechnology Co PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Genovate Biotechnology Co's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=26.85/0.102
=263.24

Genovate Biotechnology Co's Share Price of today is NT$26.85.
Genovate Biotechnology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.10.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 263.24 mean?
Genovate Biotechnology Co (ROCO:4130) has a PE Ratio of 263.24 as of Jul. 14, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Genovate Biotechnology Co and its competitors. This is 172% above median its historical median of 96.86. Over the past decade, Genovate Biotechnology Co's PE Ratio has ranged from 20.74 to 7,789.76.
Is Genovate Biotechnology Co's PE Ratio too high?
Genovate Biotechnology Co's current PE Ratio of 263.24 is 172% above median its 10-year median of 96.86. Over the past 10 years, this metric has ranged from a low of 20.74 to a high of 7,789.76. Overall, Genovate Biotechnology Co has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genovate Biotechnology Co's PE Ratio compare to VRTX and REGN?
Genovate Biotechnology Co's PE Ratio of 263.24 can be compared against companies in the Biotechnology industry. Historically, Genovate Biotechnology Co's own PE Ratio has ranged from 20.74 to 7,789.76 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Biotechnology company?
A good PE Ratio depends on the Biotechnology industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Genovate Biotechnology Co and its competitors. Genovate Biotechnology Co's current PE Ratio is 263.24, which is 172% above median its own 10-year median of 96.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genovate Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, Genovate Biotechnology Co (ROCO:4130) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$22.20, compared to a current price of NT$26.85 — trading 20.9% above its estimated fair value. The current PE Ratio is 263.24, which is 172% above median its 10-year median of 96.86. Genovate Biotechnology Co's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For Genovate Biotechnology Co (ROCO:4130), the current PE Ratio is 263.24 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genovate Biotechnology Co (ROCO:4130) Overvalued in 2026?

Based on GuruFocus' analysis, Genovate Biotechnology Co stock appears to be overvalued. The current stock price of NT$26.85 is trading 20.9% above its estimated GF Value™ of NT$22.20. GuruFocus considers Genovate Biotechnology Co to be Modestly Overvalued.

Key valuation signals for ROCO:4130:

  • PE Ratio: 263.24 (172% above median its 10-year median of 96.86)
  • GF Value™: NT$22.20 vs. price of NT$26.85 (20.9% above fair value)
  • GF Score™: 72/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4130 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genovate Biotechnology Co Business Description

Address No.1, First Industrial Road, Hsin-Chu Expanded Park, Hukou Township, Guangdong Province, Hsin-Chu county, Hsin-Chu, TWN, 303036
Genovate Biotechnology Co Ltd develops, produces, manufactures, and sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases, etc. The company is also engaged in the sales of medicines for the prevention and treatment of diseases caused by viruses and bacteria, and medicines for the treatment of cardiovascular, gastrointestinal, cancer, and autoimmune diseases etc.
72GF Score

Get the complete analysis for ROCO:4130

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$26.85
Price
NT$22.20
GF Value